National Institute for Health and Care Excellence (NICE) announced today that fremanezumab (Ajovy®) has been recommended for a restricted use within NHS England and Wales for the prevention of migraine in adults who have at least 15 or more headache days a month for more than 3 months with at least 8 of those having features of migraine and who have failed at least 3 preventive drug treatments.
We welcome this news and Dr David Bloomfield CEO of National Migraine Centre said: ”The National Migraine Centre is pleased that NICE has recognised AJOVY (Fremanezumab) as an effective new alternative preventative medication for chronic migraine, particularly given that side effects are typically much less severe than other treatments. We know that many patients will be delighted and relieved, although the treatment is only available after 3 other preventatives regimes have failed. We know from our patients that the treatment can be life transforming. ”
Ajovy is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults. Ajovy is an injectable prescription medicine, which can be self-administered.
What is the restricted criteria?
The drug may be used in patients that have at least 15 or more headache days a month for more than 3 months with at least 8 of those having features of migraine. The patient must have failed at least 3 preventive drug treatments.
What does this mean for you ?
If you live in England or Wales and have at least 15 or more headache days a month for more than 3 months with at least 8 of those having features of migraine and have failed three other preventative drug treatments then you may be eligible to be able to access Ajovy on the NHS within the coming months.
For more information click here or call us on 020 7251 3322.
At NMC our headache specialists can prescribe Ajovy privately. Book Now!